CUMYL-THPINACA (also known as SGT-42) is an indazole-3-carboxamide based synthetic cannabinoid.[1][2] CUMYL-THPINACA acts as a potent agonist for the cannabinoid receptors, with approximately 6x selectivity for CB1, having an EC50 of 0.1nM for human CB1 receptors and 0.59nM for human CB2 receptors.[3]

Legal status

Sweden's public health agency suggested to classify CUMYL-THPINACA as hazardous substance on November 10, 2014.[4]

As of October 2015 CUMYL-THPINACA is a controlled substance in China.[5]

See also

References

  1. ^ "CUMYL-THPINACA". Cayman Chemical. Retrieved 11 July 2015.
  2. ^ Monti MC, Scheurer E, Mercer-Chalmers-Bender K (July 2021). "Phase I In Vitro Metabolic Profiling of the Synthetic Cannabinoid Receptor Agonists CUMYL-THPINACA and ADAMANTYL-THPINACA". Metabolites. 11 (8): 470. doi:10.3390/metabo11080470. PMC 8398790. PMID 34436411.
  3. ^ WO 2014167530, Bowden MJ, Williamson JP, "Cannabinoid compounds", published 2014-10-16 
  4. ^ "Cannabinoider föreslås bli klassade som hälsofarlig vara". Retrieved 11 July 2015.
  5. ^ "关于印发《非药用类麻醉药品和精神药品列管办法》的通知" (in Chinese). China Food and Drug Administration. 27 September 2015. Archived from the original on 1 October 2015. Retrieved 1 October 2015.